MARKETS
Analyst Actions

Guggenheim Assumes Nanobiotix at Buy, Announces Price Target of $64

Sep 15, 2026 · 09:17 AM ET· updated 2h ago

Guggenheim analyst Paul Jeng assumes Nanobiotix (NASDAQ:NBTX) with a Buy rating and announces Price Target of $64.

Share
Why It Matters

A research team started following Nanobiotix and thinks it looks like a good buy. They believe the stock could be worth around $64 per share sometime ahead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.